| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/26/2004 | CA2494147A1 Pharmaceutical compositions for buccal delivery of pain relief medications |
| 02/26/2004 | CA2494132A1 Pharmaceutical composition, metered dose dispenser containing same, and use of pharmaceutical composition and metered dose dispenser in administering pharmaceutical agent to oral membranes |
| 02/25/2004 | EP1391516A1 Von willebrand factor (vwf)-cleaving enzyme |
| 02/25/2004 | EP1391221A1 A pharmaceutical preparation containing palladium complex compounds and the uses thereof for treating cancer and autoimmune disease |
| 02/25/2004 | EP1391213A1 Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| 02/25/2004 | EP1391211A1 Chondrogenesis promoters |
| 02/25/2004 | EP1391206A1 Pharmaceutical compositions comprising arsenic for the treatment of lymphoma |
| 02/25/2004 | EP1391205A1 Pharmaceutical composition with RNA as cofactor of hemostasis |
| 02/25/2004 | EP1391202A1 Liquid drug preparations |
| 02/25/2004 | EP1391194A1 Preparation for hair and/or scalp |
| 02/25/2004 | EP1390755A2 Assay to determine efficacy of treatment for mycobacterial infection |
| 02/25/2004 | EP1390740A1 Methods and formulations for increasing the affinity of a 1? adenosine receptor ligands for the a 1? adenosine receptor |
| 02/25/2004 | EP1390534A2 Methods for diagnosis and treatment of inflammatory bowel disease |
| 02/25/2004 | EP1390528A2 Gene markers useful for detecting skin damage in response to ultraviolet radiation |
| 02/25/2004 | EP1390508A2 A retinoic acid metabolizing cytochrome p450 |
| 02/25/2004 | EP1390497A2 Human cdnas and proteins and uses thereof |
| 02/25/2004 | EP1390496A2 Glutamate receptor modulatory proteins and nucleic acids encoding them |
| 02/25/2004 | EP1390483A2 Gene encoding molecular motor protein and diagnosis method for the disease related to the gene |
| 02/25/2004 | EP1390481A2 RECOMBINANT EXPRESSION OF hHBV REVERSE TRANSCRIPTASE (RT) |
| 02/25/2004 | EP1390478A1 Compounds capable of modulating the activity and stimulating the production of a catalytic antibody |
| 02/25/2004 | EP1390472A2 Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv |
| 02/25/2004 | EP1390468A2 Identification of essential genes of aspegillus fumigatus and methods of use |
| 02/25/2004 | EP1390410A1 Molecules for disease detection and treatment |
| 02/25/2004 | EP1390406A2 Method of modulating the proliferation of medullary thyroid carcinoma cells |
| 02/25/2004 | EP1390392A1 Methods to inhibit viral replication |
| 02/25/2004 | EP1390391A1 Transporters and ion channels |
| 02/25/2004 | EP1390385A2 Nucleic acid based modulation of female reproductive diseases and conditions |
| 02/25/2004 | EP1390383A1 Antisense permeation enhancers |
| 02/25/2004 | EP1390378A1 Pharmaceutically active uridine esters |
| 02/25/2004 | EP1390368A1 Disubstituted 7,9-guaninium halides as telomerase inhibitors |
| 02/25/2004 | EP1390365A1 Novel sulfonate substituted pyrazol pyridine dervivatives |
| 02/25/2004 | EP1390363A2 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method |
| 02/25/2004 | EP1390353A1 Triazole-derived kinase inhibitors and uses thereof |
| 02/25/2004 | EP1390077A2 Treatment and diagnosis of macrophage mediated disease |
| 02/25/2004 | EP1390075A2 Chemotherapeutic induction of egr-1 promoter activity |
| 02/25/2004 | EP1390073A2 Compositions having enhanced pharmacokinetic characteristics |
| 02/25/2004 | EP1390072A2 Use of an ampa receptor potentiator for the manufacture of a medicament for the treatment of type 2 diabetes |
| 02/25/2004 | EP1390071A2 Symbiotic regenerative agent |
| 02/25/2004 | EP1390070A1 Use of il-18 inhibitors for treating or preventing cns injuries |
| 02/25/2004 | EP1390068A1 Methods and formulations of using a1 adenosine and p2x purinoreceptor antagonists |
| 02/25/2004 | EP1390067A1 Compositions for use in treating ige-associated disorders |
| 02/25/2004 | EP1390057A2 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and method of use |
| 02/25/2004 | EP1390046A2 Treatment of neoplasms with viruses |
| 02/25/2004 | EP1390045A1 The use of a compound with a negatively charged domain of radicals for the treatment of restenosis |
| 02/25/2004 | EP1390041A1 Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception |
| 02/25/2004 | EP1390040A1 Pharmaceutical composition for use in hormone replacement therapy |
| 02/25/2004 | EP1390039A1 Use of estrogen compounds to increase libido in women |
| 02/25/2004 | EP1390038A2 Treatment of conditions relating to hormone deficiencies by administration of progestins |
| 02/25/2004 | EP1390037A1 Methods for treating delirium using glucocorticoid receptor-specific antagonists |
| 02/25/2004 | EP1390033A1 Farnesyl protein transferase inhibitors for treating cachexia |
| 02/25/2004 | EP1390032A2 Novel quaternary ammonium compositions coupled with facilitating anions and their use in kits, as well as their use in preventing and treating certain conditions |
| 02/25/2004 | EP1390031A2 Topical composition containing a fungicide |
| 02/25/2004 | EP1390029A1 Phenylindoles for the treatment of hiv |
| 02/25/2004 | EP1390023A2 Pharmaceutical salts |
| 02/25/2004 | EP1390021A1 Delivery of compounds for the treatment of migraine through an inhalation route |
| 02/25/2004 | EP1390019A1 Controlled release drug delivery device |
| 02/25/2004 | EP1389911A1 Ectoparasiticidal compositions and methods of their use |
| 02/25/2004 | EP1239879B1 Formulations of adenosine a1 agonists and cox2-inhibitors |
| 02/25/2004 | EP1239878B1 Formulations of adenosine a1 agonists and 5ht1 agonists |
| 02/25/2004 | EP1222171B1 Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof |
| 02/25/2004 | EP1140931B1 5ht1 antagonists for antidepressant therapy |
| 02/25/2004 | EP1117392B1 Method for preventing or delaying catheter-based revascularization |
| 02/25/2004 | EP1032402B1 Use of citicoline for the treatment of multiple sclerosis (MS) |
| 02/25/2004 | EP0981620B1 Hgf polypeptides and their use in therapy |
| 02/25/2004 | EP0948308B1 Methods for treating skin pigmentation |
| 02/25/2004 | EP0866861B1 Molecular cloning and characterization of molecules related to relaxin and the insulin family of ligands |
| 02/25/2004 | EP0831834B1 Debromohymenialdisine and related compounds for treating osteoarthritis |
| 02/25/2004 | EP0825853B1 Prolonged nerve blockage by the combination of local anesthetics and glucocorticoids |
| 02/25/2004 | EP0820515B1 Phospholipase c homolog |
| 02/25/2004 | CN1478145A Differentiated cells suitable for human therapy |
| 02/25/2004 | CN1478143A Tumor cell internal specific proliferated virus capable of high-effectively expressing tumor angiogenesis inhibiting factor and its application |
| 02/25/2004 | CN1478098A Modulation of IL-2-and IL-15-mediated T cell responses |
| 02/25/2004 | CN1478087A Indolylmaleimide derivatives as protein kinase C inibitors |
| 02/25/2004 | CN1478085A ABCA-1 elevating compounds against coronary artery disease or atherosclerosis |
| 02/25/2004 | CN1478076A MCH antagonists and their use in treatment of obesity |
| 02/25/2004 | CN1477977A Compositions of N-(methy/ethy/aminocarbony/)-4-(3-methy/pheny/amino)-3-pyridy/sulfonamide and cyclic oligosaccharides |
| 02/25/2004 | CN1477976A Combination of GABA agonists and aldose reductase inhibitors |
| 02/25/2004 | CN1477975A Combination of GABA agonists and sorbitol dehydrogenase inhibitors |
| 02/25/2004 | CN1477968A Methods for treating rheumatic diseases using soluble CTLA4 molecule |
| 02/25/2004 | CN1477964A Treatment of neoplasms with viruses |
| 02/25/2004 | CN1477960A EPA receptor inhibitors to treat rheumatoid arthritis |
| 02/25/2004 | CN1477959A Compositions and methods for lowering plasma lipoprotein (a) and risk factors of cardiovascular diseases |
| 02/25/2004 | CN1477958A Composition and method |
| 02/25/2004 | CN1477953A Process for preparing pharmaceutical compositions for use with soft gelatin formulations |
| 02/25/2004 | CN1477950A Supplement to be enterally administered for parenteral nutrition or partial enteral/oral nutrition of critically ill, chronically ill and people with malnutrition |
| 02/25/2004 | CN1476900A Adjustable controllable tumor eiving vacine and its preparation method |
| 02/25/2004 | CN1476833A Preparation method of medicine for curing urteriosclerosis by using CS-866, losartan and candisartan |
| 02/25/2004 | CN1139403C Ophthalmic composition comprising beta-blocker |
| 02/25/2004 | CN1139389C Food and its making method |
| 02/25/2004 | CN1139384C Therapeutic composition based on flavonoids for use in treatment of tumours with cytotoxic agents |
| 02/24/2004 | US6696567 Pyrrolo[2,3-d]pyrimidine compounds |
| 02/24/2004 | US6696556 Genetic engineering |
| 02/24/2004 | US6696495 Treatment of disorders secondary to organic impairments |
| 02/24/2004 | US6696485 Cocoa extracts; antitumor, anticancer activity; oxidation resistance; dna topoisomerase ii enzyme inhibition |
| 02/24/2004 | US6696483 Administering golgi apparatus disturbing agents such as brefeldin a, nocodazole, ilimaquinone, bafilamycin, okadaic acid, retinoic acid, and mixtures |
| 02/24/2004 | US6696480 Antilipemic, anticholesterol agent |
| 02/24/2004 | US6696478 Compound targeted to protein kinase c enzyme |
| 02/24/2004 | US6696467 Quinoline derivatives |
| 02/24/2004 | US6696454 Inhibitors of spermidine synthase for the treatment of osteoarthritis and cartilage rehabilitation |
| 02/24/2004 | US6696453 Use of NF-κB inhibitors to treat dry eye disorders |